

that closure of polyps is an important long-term outcome. In our study, we reported 6 months' results of anti-VEGF monotherapy. Further studies investigating long-term outcome are warranted.

*Jay Kumar Chhablani, Ritesh Narula,  
Raja Narayanan*

Smt. Kanuri Santhamma Retina Vitreous Service,  
LV Prasad Eye Institute, Kallam Anji Reddy Campus,  
Banjara Hills, Hyderabad - 500 034, Andhra Pradesh, India

Correspondence to: Dr. Raja Narayanan,  
Smt. Kanuri Santhamma Retina Vitreous Service, LV Prasad Eye  
Institute, Kallam Anji Reddy Campus, Banjara Hills, Hyderabad -  
500 034, Andhra Pradesh, India. E-mail: narayanan@lvpei.org

## Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy

Dear Editor,

We thank the authors for their comments. We agree with the comments regarding other treatment options for polypoidal choroidal vasculopathy (PCV). PDT may be considered alone or in combination with anti-vascular endothelial growth factor (VEGF) drugs. However, anti-VEGF drugs alone also have a significant effect on visual improvement as shown in various studies. As mentioned by the authors, we agree

### Access this article online

Access this article online	
<b>Quick Response Code:</b>	<b>Website:</b> www.ijo.in
	<b>DOI:</b> 10.4103/0301-4738.126197